Heart Test Laboratories, Inc. (HSCS)
NASDAQ:HSCS
HSCS Stock Chart & Stats
$3.35
-$0.05(-1.44%)
At close: 4:00 PM EST
$3.35
-$0.05(-1.44%)
Day’s Range― - ―
52-Week Range$2.01 - $6.47
Previous CloseN/A
Volume8.49K
Average Volume (3M)58.86K
Market Cap
$7.32M
Enterprise Value-$3.39B
Total Cash (Recent Filing)$3.40B
Total Debt (Recent Filing)$3.87M
Price to Earnings (P/E)―
Beta1.53
Next Earnings
Jul 22, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.71
Shares Outstanding3,184,700
10 Day Avg. Volume93,774
30 Day Avg. Volume58,857
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)16.05
Price to Sales (P/S)757.08
P/FCF Ratio-0.44
Enterprise Value/Market Cap-462.56
Enterprise Value/Revenue-390.84K
Enterprise Value/Gross Profit36.86K
Enterprise Value/Ebitda442.53
Forecast
1Y Price Target
$12.00Price Target Upside258.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-3.68
Revenue Forecast (FY)$50.00K
Bulls Say, Bears Say
Bulls Say
Clinical InnovationAI-enhanced ECG software aims to expand the clinical usefulness of the standard ECG by improving detection of heart disease.
Market OpportunityMyoVista Insights cloud platform targets hospital ECG management workflows, creating a large commercial opportunity for cloud-based ECG services.
Reimbursement SupportAvailability of CPT reimbursement codes for the MyoVista Insights platform supports potential revenue generation through routine medical billing.
Bears Say
Commercialization DelayInitial revenue for the MyoVista Insights platform has been delayed, which pushes back commercialization and delays progress toward cash flow breakeven.
Dilution And Execution RiskPotential share-count dilution combined with execution challenges represents a key risk that could pressure the stock and reduce shareholder value.
Funding RequirementSignificant additional capital will likely be required to finance commercialization following FDA approvals, increasing financing risk for shareholders.
Heart Test Laboratories, Inc. News
HSCS FAQ
What was Heart Test Laboratories, Inc.’s price range in the past 12 months?
Heart Test Laboratories, Inc. lowest stock price was $2.01 and its highest was $6.47 in the past 12 months.
What is Heart Test Laboratories, Inc.’s market cap?
Heart Test Laboratories, Inc.’s market cap is $7.32M.
When is Heart Test Laboratories, Inc.’s upcoming earnings report date?
Heart Test Laboratories, Inc.’s upcoming earnings report date is Jul 22, 2026 which is in 110 days.
How were Heart Test Laboratories, Inc.’s earnings last quarter?
Heart Test Laboratories, Inc. released its earnings results on Mar 12, 2026. The company reported -$0.71 earnings per share for the quarter, the consensus estimate of -$0.71 by $0.
Is Heart Test Laboratories, Inc. overvalued?
According to Wall Street analysts Heart Test Laboratories, Inc.’s price is currently Undervalued.
Does Heart Test Laboratories, Inc. pay dividends?
Heart Test Laboratories, Inc. does not currently pay dividends.
What is Heart Test Laboratories, Inc.’s EPS estimate?
Heart Test Laboratories, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Heart Test Laboratories, Inc. have?
Heart Test Laboratories, Inc. has 3,184,700 shares outstanding.
What happened to Heart Test Laboratories, Inc.’s price movement after its last earnings report?
Heart Test Laboratories, Inc. reported an EPS of -$0.71 in its last earnings report, expectations of -$0.71. Following the earnings report the stock price went up 1.102%.
Which hedge fund is a major shareholder of Heart Test Laboratories, Inc.?
Currently, no hedge funds are holding shares in HSCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Heart Test Laboratories, Inc.
HeartSciences Inc., a medical technology company, focuses on applying AI-based technology to an ECG to expand and improve clinical usefulness. It develops artificial intelligence-enhanced electrocardiography (AI-ECG) solutions, an algorithm to detect impaired cardiac relaxation or cardiac dysfunction caused by heart disease and/or age-related cardiac dysfunction; MyoVista wavECG device, a resting 12-lead ECG that provides diagnostic information related to cardiac dysfunction, as well as conventional ECG information in the same test; and MyoVista Insights, a cloud-based platform to host AI-ECG algorithms on an ECG hardware agnostic basis. The company was formerly known as Heart Test Laboratories, Inc. and changed its name to HeartSciences Inc. in October 2024. HeartSciences Inc. was incorporated in 2007 and is headquartered in Southlake, Texas.
HSCS Stock 12 Month Forecast
Average Price Target
$12.00
▲(258.21% Upside)
Technical Analysis
Strata Skin Sciences
―
Biomerica
―
PAVmed
―
Tenon Medical, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
2.49% Insiders
0.36% Mutual Funds
4.51% Other Institutional Investors
92.08% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---